Skip to main content

Evaluation of HPV Genotyping Assays for Archival Clinical Samples.

Lillsunde Larsson G, Carlsson J, Karlsson MG, Helenius G

Publication: J Mol Diagn (2015) • Vol 17 • Page 293-301PMID: 25791291View on PubMed

Purpose

The purpose of this paper was to compare Human papillomavirus (HPV) genotyping results generated by 4 different methods from formalin-fixed, paraffin-embedded (FFPE) tissue specimens.

Conclusion

68% of specimens (67 of 99) were found to be HPV positive using the in house real-time PCR and by pyrosequencing, but 72% (71 of 98) and 82% (81 of 99) of specimens were found to be HPV positive using the CLART HPV2 and Anyplex II HPV28 assays, respectively. All assays assigned the same genotype for 55 of the 99 specimens, and for an additional 25 specimens, there was agreement between 3 of the 4 assays, with deviating results most often due to detection of additional genotypes using the Anyplex II HPV28 method (18 of 25 specimens). Importantly, when compared to the reference in-house real-time PCR method, Anyplex II HPV28 assays were 100% sensitive but displayed only 56% specificity due to detection of additional genotypes not included in the in-house method.

Studies (1)

Purpose

The purpose of this study was to compare HPV genotyping results generated by 4 different methods from archived FFPE specimens. 99 FFPE specimens from patients suspected to have HPV were used in this study, including 60 cervical lesions, 20 penile carcinomas, 5 vulva specimens, 4 skin specimens, 3 head or neck specimens, 2 larynx specimens, 2 anal specimens, 1 bladder specimen and 1 vaginal specimen. DNA was extracted from 4 5-20 µm deparaffinized and proteinase K-digested sections using the QIAamp DNA mini kit. DNA was analyzed using in-house real-time PCR assay, the real-time PCR based Anyplex II HPV28 assay, the low density array based CLART HPV2 and pyrosequencing of MPV5+/6+.

Summary of Findings

All 99 specimens were successfully genotyped with an in-house real-time PCR (reference method), the real-time PCR based Anyplex II HPV28 assay, and pyrosequencing, and 98 of 99 were successfully genotyped using the low density array based CLART HPV2. 68% (67 of 99) were found to be HPV positive using the in-house real-time PCR and by pyrosequencing, but 72% (71 of 98) and 82% (81 of 99) were found to be HPV positive using the CLART HPV2 and Anyplex II HPV28 assays, respectively.  All assays assigned the same genotype for 55 of the 99 specimens, and for an additional 25 specimens, there was agreement between 3 of the 4 assays, with deviating results most often obtained using Anyplex II HPV28 (18 specimens) and CLART HPV2 (5 specimens). Importantly, the divergent results obtained using Anyplex II HPV28 were due to detection of an additional genotype (12 of 18 specimens) or detection of HPV in a specimen classified as negative by the other methods (6 of 18 specimens), but the divergent results obtained using CLART HPV2 were due to different reasons. When the 14 genotypes generated by the reference method were considered to be the standard, sensitivity and concordance were highest using the Anyplex II HPV28 assays (100% and 97%, respectively), but the specificity was higher using the CLART HPV 2 and pyrosequencing (97%, both versus 91%). When all genotypes were considered, data generated by Anyplex II HPV28 was significantly different from the reference method (p<0.001), but still this method was 100% sensitive relative to the reference protocol. As expected, when all genotypes were considered, specificity relative to the reference method decreased to 56% for Anyplex II HPV28, 68% for CLART HPV2 and 88% for pyrosequncing. 

  • Biospecimens

    TissueVagina
    TissueCervix
    TissueVulva
    TissueLarynx
    TissueSkin
    TissueBladder
    TissueLymph Node
    TissueOther
  • Preservation Types

    Formalin
  • Diagnoses

    Other diagnoses
    NeoplasticCarcinoma
    Not specified
  • Platforms

    DNALow density array
    DNADNA sequencing
    DNAReal-time qPCR
    DNASNP assay
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Real-time qPCR SpecificTargeted nucleic acid
    HPV E6
    HPV E7
    Real-time qPCR SpecificTechnology platform
    Anyplex II HPV28
    CLART HPV2
    In-house real-time PCR
    Pyrosequencing